Skip to main content

Novo Nordisk

By Jessica Hagen | 12:24 pm | June 27, 2025
The announcement comes the same week the pharma giant ended its collaboration with Hims & Hers to sell Wegovy, alleging the company engages in deceptive marketing and illegally sells copycat drugs.
By Jessica Hagen and Anthony Vecchione | 02:36 pm | June 24, 2025
The partnership has been terminated less than two months after launch as Novo Nordisk alleges Hims & Hers is illegally selling copycat drugs and using deceptive marketing practices.
By Jessica Hagen | 03:58 pm | April 30, 2025
Americans with a prescription will have access to Novo Nordisk's obesity drug Wegovy through the Hims & Hers platform for $599 monthly.
By Adam Ang | 03:51 am | August 10, 2023
Novo Nordisk is bringing its expertise in chronic disease management to Kakao's mobile diabetes app.
By Adam Ang | 04:40 am | March 14, 2022
The partnership includes a patient support programme that brings tailored and age-based educational content to patients with Type 1 diabetes.
By Laura Lovett | 03:53 pm | April 07, 2021
The integration is aimed at boosting data collection. 
By Dean Koh | 01:22 am | March 05, 2019
Health2Sync and Novo Nordisk Pharma Ltd.
By Jonah Comstock | 12:04 pm | February 20, 2019
Abbott joins Dexcom, Glooko and Roche as a data-sharing partner for the as-yet-unlaunched device.
By Laura Lovett | 05:23 pm | February 18, 2019
This morning Glooko also announced that its diasend platform will be compatible with the Dexcom G6. 
By Dave Muoio | 05:17 pm | June 25, 2018
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players.